Drug Trial Radar · NCT06077877
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Actual
Start
Oct 24, 2023
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Conditions
- Neoplasms
Interventions
GSK4524101Drug
GSK452101 will be administered.
NiraparibDrug
Niraparib will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Proportion of Participants with Dose Limiting Toxicities (DLTs) during DLT Observation PeriodTime frame: Up to 28 days
- Part 1 - Proportion of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) based on Severity during DLT Observation PeriodTime frame: Up to 28 days
- Part 1 - Duration of Treatment Emergent AEs and SAEs (Days) during DLT Observation PeriodTime frame: Up to 28 days
- Part 1 - Percentage of Participants who receive all Planned Doses during DLT Observation PeriodTime frame: Up to 28 days
- Part 1 -Percentage of Participants who require dosage interruptions, dose reductions, and drug discontinuations due to adverse reactions during DLT Observation PeriodTime frame: Up to 28 days
- Part 2 - Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 52 weeks
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
San Francisco, California
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Fairfax, Virginia
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Panama City, Panama
GSK Investigational Site
Punta Pacifica Panama City Panama, Panama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.